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Letters
Prostatitis and Benign Prostatic
Hyperplasia: Emerging Infectious
Diseases?
To the Editor: In their excellent article,
Molecular Approaches to the Identification of
Unculturable Infectious Agents, Gao and Moore
(1) point out that molecular approaches should be
unleashed on diseases such as sarcoidosis, Kawa-
saki disease, and type I diabetes mellitus, which
are thought but not proven to be infectious. The
authors, however, are overlooking the more com-
mon and most likely infectious disease of unknown
etiology today—prostatitis.
According to the pathologist McNeal, the
prostate gland is the most commonly diseased
internal organ of the human body (2). Prostatitis
is the most common prostate disease, resulting in
more physician visits than either benign pros-
tatic hyperplasia or prostate cancer, according to
the National Institutes of Health (3). Despite its
frequency, prostatitis as a disease and as a histo-
logic lesion is understudied (4).
By the Meares and Stamey culture localization
procedure, in which the first voided urine, a mid-
stream urine, the expressed prostatic secretions,
and a final voided urine are compared, more than
90% of cases in patients with chronic pelvic symp-
toms are labeled as “nonbacterial” prostatitis or
prostatodynia, both of which are thought to be
incurable diseases (5).
The University of Washington has documented
white blood cell counts as high as 38,000 per mm3,
in “nonbacterial” prostatitis patients (6). Accord-
ing to urologist Thomas Stamey, up to 50% of all
men experience symptoms of prostatitis during
Emergence of Epidemic O’nyong-
nyong Fever in Southwestern Uganda,
After an Absence of 35 Years
To the Editor: In July 1996, an uncommon disease
suspected to be O’nyong-nyong fever was recog-
nized in the Rakai district of southwestern Uganda.
It was reported to have started in June 1996. The
disease spread into the neighboring Mbarara and
Masaka districts of Uganda and in the bordering
Bukoba district of northern Tanzania.
The initial symptoms of O’nyong-nyong fever
are high fever and generalized maculopapular
skin rash with crippling arthritis, primarily in the
big joints, in the absence of joint effusion. Other
features are lymphadenitis, eye pain and
reddening with no discharge, chest pain, and
general malaise. The disease is self-limiting. All
age groups and both sexes are equally affected. In
areas where the disease is epidemic, 60% to 80%
of the people are infected, and familial clustering
is found in affected households. No deaths have
been reported, but two miscarriages have been
associated with infection.
The Ministry of Health (Uganda), in
collaboration with the Uganda Virus Research
Institute, began epidemiologic and clinical inves-
tigations of the epidemic in August 1996. Acute-
phase serum samples were collected from
patients, and adult mosquitoes were collected
from within and around patients’ homes. Virus
isolates were made from acute-phase serum
samples from several patients by intracranial
inoculation and passage in baby mice. Attempted
virus isolations from mosquito specimens are in
progress. Serum samples and aliquots of the
virus isolates were sent to the Centers for
Disease Control and Prevention, Fort Collins,
Colorado, USA, for reisolation and identification.
A portion of the capside and NS4  genes of the
virus isolates was sequenced and identified as
O’nyong-nyong virus; the virus was isolated and
sequenced directly from another serum sample.
Two serum samples were positive for IgM
antibody to O’nyong-nyong antigen.
O’nyong-nyong virus was responsible for a
similar epidemic in 1959 to 1961, which started
in northern Uganda and spread south and
eastward into Kenya, Tanzania, and Zambia, and
then northward from Tanzania into southwestern
Uganda, where it subsided. The disease has
reemerged in this area after 35 years of absence.
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Letters
Risk Factors for Severe Leptospirosis
in the Parish of St. Andrew, Barbados
To the Editor: Leptospirosis, an important
zoonosis in most warm-climate areas, is endemic
in most Caribbean countries (1). The disease was
first reported in Barbados 60 years ago (2), and
since 1979 has been the subject of continual study
as the result of the establishment of the Lepto-
spira Laboratory by the governments of Barbados
and the United Kingdom. The annual incidence of
severe leptospirosis in Barbados over the past 17
years has been approximately 11.5 cases per
100,000 population with a death rate of 13%.
However, the incidence rate varies in the parishes
of Barbados. For the 12-year period from 1979 to
1991, the lowest incidence rates were in St. Peter
(9.5 cases per 100,000 population) and St. Michael
(9.9 cases per 100,000 population), while the high-
est was in St. Andrew (40 cases per 100,000
population). This greater than fourfold difference
in incidence rates has been attributed to dif-
ferences in rainfall (3). We performed a retro-
spective case-control study to determine what
other factors were important.
their lifetimes (7). The prostatitis lesion was found
in 40 (44%) of 91 men at random autopsy (8). In
another study of 100 consecutive autopsies on
men who died suddenly in automobile accidents
and from other causes, the prevalence of
histologic signs of prostatitis increased with age
and was highest when benign prostatic
hyperplasia was also present. Prostatitis was
present in 22% of men under 40 years of age and
in 60% of those over 40 years of age (9).
In fact, the line between benign prostatic
hyperplasia and prostatitis is blurred. Prostatitis
as a histologic lesion has been found in 98% of
patients with benign prostatic hypertrophy (10).
Microbial tests on benign prostatic hyperplasia
tissue have found significant rates of infectivity.
In another study, more than 70% of transurethral
resection of the prostate specimens showed clinical
or laboratory signs of infection (11). Benign pros-
tatic hyperplasia and prostatitis cannot be dis-
tinguished by symptoms, and some believe that
they may be the same disease.
In these days of prostate specific antigen
testing, more than 50% of men who undergo biop-
sies for prostate cancer have a prostatitis lesion
whether they have cancer or not (Gottesman et
al., unpublished data; McNeal, personal communi-
cation, 1995). Prostatitis occurs at an early age,
and prostate cancer decades later, in the same
part of the prostate gland, the peripheral zone.
Why aren’t DNA techniques being unleashed
on what is apparently the most common and most
purulent unknown inflammatory disease in
men—an inflammatory lesion that is associated
with benign prostatic hyperplasia and prostate
cancer? Surely, DNA microbial testing has
important implications for all three major prostate
diseases—prostatitis, benign prostatic hyper-
plasia, and prostate cancer.
Brad Hennenfent
Director, The Prostatitis Foundation
Chicago, Illinois, USA
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